31P-MRS Myocardial Energetic Phenotyping and Prognosis Across the Cardiac Disease Spectrum

Condition(s) studied

Study summary

The study is designed to establish a comprehensive myocardial energetic phenotype across a broad spectrum of cardiovascular diseases using phosphorus-31 magnetic resonance spectroscopy (31P-MRS).

And the study plans to enroll 1,000 participants, comprising healthy volunteers and patients with diverse cardiac conditions. Target cohorts primarily encompass heart failure syndromes and various cardiomyopathies, with a particular focus on non-ischemic and hypertrophic phenotypes, as well as ischemic and other structural etiologies.

By integrating 31-MRS with multiparametric standard CMR, this study aims to map disease-specific metabolic signatures. The primary outcome measure is the myocardial PCr/ATP ratio, serving as a direct in vivo marker of energetic impairment. Furthermore, the study aims to explore the coupling between metabolic phenotypes and structural remodeling (tissue characterization), mechanical dysfunction, and systemic clinical biomarkers. Crucially, the study will evaluate the prognostic value of these energetic phenotypes in predicting clinical outcomes, ultimately providing novel insights into the pathophysiology and risk stratification of cardiomyopathies and heart failure.

Eligibility

Primary outcome measure(s)

• Myocardial phosphocreatine to ATP ratio (PCr/ATP) — At baseline CMR examination
  Myocardial PCr/ATP measured by 31P magnetic resonance spectroscopy

Trial sites (1)

More Chinese Academy of Medical Sciences, Fuwai Hospital trials in China

Other trials for the same condition